Biotech_Jack (@biotech_jack) header
Biotech_Jack (@biotech_jack) profile picture
Mars
Joined June 2021
Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)Photo by Biotech_Jack (@biotech_jack)
Listen. I'm Adam enough to admit when I've been out-Adam'd. If you're looking for scientific rebukes of some of the finer technical points in the Scorpion $ABVX report, read through this thread. Fortunately for all of us, essentially all of the points are so easily disproven that each refutation only requires a single line of text. This dude bodies Scorpion here. Absolute Adam.
2
401
$ABVX All I have to say is that if any of these was true FDA, EMA and worldwide health agencies would have placed clinical hold by now and not let trials run for 10+ years. Good luck.
2
404
Biotech_Jack retweeted
My unserious rebuttal to @ScorpionFund's short report 🧵
4
16
3
117
13,809
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
1
817
Biotech_Jack retweeted
$RVMD Lifesci PT $338 $RVMD: status quo maintained within pan-RAS space; headline figures include 60.7% ORR, 11.1 months mDOR, 12.8 months mPFS, and 76.6% landmark OS at 12 months in N=61 frontline PDAC patients with 18.3 months median follow-up (see also Prior AACR 2026 Data). We'd also flag an 8.2% rate of CR, as well as a 95% CI for mPFS ranging from 10.8-18.4 months. Competitor $ERAS reads out a larger N but nonetheless early (and somewhat uninterpretable) dataset that clears a minor overhang for $RVMD
$RVMD TRUIST BUY PT$261 Near term,expect investors to focus on tomorrow’s ERAS-0015 believe the principal debate will center on response depth, particularly in KRAS G12D PDAC. Expectations for ERAS-0015 appear to call for ~40-50% overall ORR and potentially 50%+ in G12D, in our investor discussions, which would compare favorably with Rasonque monotherapy’s 30% overall ORR and 24% ORR in G12D. That said, we believe ORR alone is unlikely to resolve the competitive debate. Rasonque has already demonstrated statistically significant OS benefit across RAS subtypes in a randomized ph.III study, including a 0.49 OS HR in G12D, while becoming increasingly entrenched in 2L+ PDAC. In our view, ERAS-0015 and other competitors would ultimately need durable survival data and likely a head-to-head study against Rasonque to fully establish clinically meaningful superiority. Bottom line: focus remains on Rasonque launch execution and its expansion into 1L PDAC
5
14
4,932
This are only the shorts on french shares.
Abivax : Shay Capital franchit le seuil de publication, 0,59 % du capital vendu à découvert. Déclaré à l'AMF le 17 novembre. 5 fonds sont déclarés vendeurs, 5,67 % du capital au total. $ABVX
1
207
$ABVX new patent granted "Quinoline derivatives for use in treatment of inflammation diseases"
1
9
1,230
I really don’t like how is left hand is moving
Stanley Druckenmiller: "We're looking for AI use cases as opposed to infrastructure" "Maybe the most interesting use case is a lab..." "I don't personally believe they're gonna be in the token business for much longer...you can start selling tasks"
7
9
4
465
134,591
Biotech_Jack retweeted
AMD CEO Lisa Su says Nvidia is a phenomenal company and Jensen has been a tremendous leader, but AMD has to separate itself from the noise "First of all, Nvidia is a phenomenal company. Jensen has been a tremendous leader for the industry, a great leader." "There is a lot going on. What I try to do from an AMD standpoint, and from an industry standpoint, is, look, we have to separate a little bit from the noise. The noise will work itself out in time." "But taking a step back, from an AMD standpoint, we are in a place where we have just tremendous opportunity." "Tremendous opportunity to be part of this infrastructure buildout, to work collectively with our partners on the roadmap going forward, to, I'm not gonna say overpromise, but to promise and exceed expectations in terms of delivery."
AMD CEO Lisa Su says this semiconductor cycle does not look cyclical, it looks ‘generational’ "I think this one is a little different." "Typically, the semiconductor market has been known to be a cyclical market. When demand is high, you build a lot, and then you satisfy that demand, and then there's a little bit of a digestion period." "We are not seeing that today. We're not seeing something that looks cyclical. We're seeing something that looks generational in terms of the growth that's required." "Because AI is eventually making every company, every enterprise, more productive, and so you're willing to invest in that productivity so that you build better products. It's like a virtuous, positive cycle." "Now, that being the case, we are always looking at ensuring that the investment is coincident with the return on investment. That's a very regular conversation that we have. But this cycle does feel quite different."
2
24
5
179
241,515
$ABVX Top5 ADR Holder 1/ Helikon Investments Ltd 4,222,896 4.82% Darwin Global Management Ltd 4,021,583 4.59% Vestal Point Capital LP 3,960,000 4.52% TCG Crossover Management LLC 3,663,038 4.18% Adar1 Capital Management LLC 2,050,822 2.34%
2
30
2,937
$ABVX ADR 2/2 HIGEST INCREASE OR NEW POSITION Jupiter Topco LLC +1,913,933 (New) 2.19% Vestal Point Capital LP +1,610,557 (Incr) 4.52% Helikon Investments Ltd +1,435,765 (Incr) 4.82% RA Capital Management LP +1,132,557 (New) 1.29% Norges Bank +1,100,000 (New) 1.26%
1
5
863
GS: We forecast the S&P 500 will rise by 17% to 8,700 by year-end 2027
16
45
11
359
49,350
$PHVS Top 5 holders 1/ FMR LLC (Fidelity) 6,921,820 9.86% Wellington Management Group LLP 6,696,804 9.54% Foresite Capital Management LLC 5,442,723 7.75% venBio Partners LLC 4,458,977 6.35% EQT AB (including LSP V) 3,424,609 4.88%
1
213
$PHVS 2/ Wellington Management Group LLP (13G) +4,303,870 6.13% (Total: 9.54%) Point72 Asset Management LP (ULT-AGG) +1,258,567 1.79% (Total: 4.13%) Vanguard Group Inc. (ULT-AGG) +1,174,010 1.67% (Total: 1.91%) Tetragon Partners GP Ltd (13F) +542,620 0.77% (Total: 1.19%)
1
151
$PHVS 3/3 Polar Capital Partners Ltd (ULT-AGG) +466,979 0.67% (Total: 3.98%)
125
$NAMS Top 5 Holder Frazier Life Sciences Management LP 18,988,902 15.83% Capital Group Cos Inc/The 14,723,654 12.28% FMR LLC (Fidelity) 11,941,763 9.96% RA Capital Management LP 9,550,191 7.96% Forbion 8,490,353 7.08% 1/
1
4
428
$NAMS 2/2 Jupiter Topco LLC +2,535,682 (New) 2,535,682 2.11% Bain Capital Life Sciences +1,632,646 (Incr) 3,806,559 3.17% Two Sigma Investments LP +1,123,080 (incr) 1,135,081 0.95% Capital Group Cos Inc/The +769,602 (incr) 14,723,654 12.28% Norges Bank +645,383 (incr) 1,134,823
1
129
Patience
4
17
1
182
8,814
Druckenmiller increase $NAMS holdings
Druckenmiller 13F summary: - bought STX (and calls), NEM, APP, SPCX, PLTR, - added AMZN, U, FOXA, - reduced TSMC, STM, INSM, PANW - dumped SNDK, EWZ, GOOGL, UAL
4
314